Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 4:05 PM EDTAdvanced RG6501 (OpRegen®) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: Spine Completed Key Activities to Support Planned Regulatory Interactions for OPC1 and VAC2 Expanded Collaboration with Advanced BioMatrix for HyStem® Cell Drug Delivery Technology Cash, Cash Equivalents, and Marketable Securities of $72.0 Million as of June 30, 2022 Expected to Provide Capital Through Q2 2024
CARLSBAD, Calif.--(BUSINESS... More
